Kyverna Therapeutics, Inc. (KYTX)
(Delayed Data from NSDQ)
$8.23 USD
+0.58 (7.58%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $8.26 +0.03 (0.36%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
KYTX 8.23 +0.58(7.58%)
Will KYTX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for KYTX based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for KYTX
Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment
Buy Rating for Kyverna Therapeutics Amid FDA Clearance and Promising Phase 2 Trial Prospects
Oppenheimer doesn't understand why Cartesian hit by emerging CAR-T short thesis
Kyverna Therapeutics participates in a conference call with JPMorgan
Kyverna Therapeutics participates in a conference call with JPMorgan